Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$99.64 USD

99.64
895,466

-0.89 (-0.89%)

Updated May 28, 2024 03:53 PM ET

After-Market: $99.65 +0.01 (0.01%) 4:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (152 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mark Vickery headshot

Medicare Drugs Targeted Under Inflation Reduction Act

by Mark Vickery

Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca

by Zacks Equity Research

Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.

AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis

by Zacks Equity Research

AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.

Novartis (NVS) Announces Positive Long-Term Data on Leqvio

by Zacks Equity Research

Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.

Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar

by Zacks Equity Research

Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.

Sanghamitra Saha headshot

Oncology Market's Huge Potential Puts These Stocks in Focus

by Sanghamitra Saha

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?

by Zacks Equity Research

AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.

Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca

by Zacks Equity Research

Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article

Kinjel Shah headshot

5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace

by Kinjel Shah

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.

Novartis (NVS) Plans to Spin-Off Sandoz in Early October

by Zacks Equity Research

Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug

by Kinjel Shah

FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.

Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth

by Zacks Equity Research

Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk

by Kinjel Shah

Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.

Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates

by Zacks Equity Research

Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2

by Zacks Equity Research

Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales.

Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.

Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.

Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

by Zacks Equity Research

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.

Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.

How Will Pfizer's (PFE) Key Drugs Perform in Q2 Earnings?

by Zacks Equity Research

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.

Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.

Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered

by Zacks Equity Research

Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.